Information Provided By:
Fly News Breaks for July 14, 2015
FPRX
Jul 14, 2015 | 08:11 EDT
Oppenheimer believes that Five Prime's FPA008 will show better safety and tolerability versus other treatments for PVNS, a benign rare tumor treated with surgery, but with a 56% relapse rate. The firm expects data from a recently initiated study of FPA008 to be announced at the end of this year or early 2016. It reiterates an Outperform rating on Five Prime.
News For FPRX From the Last 2 Days
There are no results for your query FPRX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.